Amer Ahmed A, Amer Samar A, Alrufaidi Khaled Masoud, Abd-Elatif Eman Elsayed, Alafandi Bana Zuhair, Yousif Dalia Abdelmonaim, Armi Nadia Toukah, Alkhalaf Atheer Abdulaziz, Shah Jaffer, Ramadan Mohamed Sh
Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Department of Public Health and Community Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Front Reprod Health. 2022 Jul 22;4:927211. doi: 10.3389/frph.2022.927211. eCollection 2022.
By September 2, 2021, over 30,000 COVID-19-vaccinated females had reported menstrual changes to the MHRA's Yellow Card surveillance system. As a result, the National Institutes of Health (NIH) is urging researchers to investigate the COVID-19 vaccine's effects on menstruation. Therefore, this study was conducted to explore the menstrual changes after COVID-19 vaccination and/or SARS-CoV-2 infection and their interrelations with demographic, mood, and lifestyle factors in Arab women of childbearing age (CBA).
A cross-sectional study was conducted during October 2021 using an Arabic validated and self-administrated questionnaire. In total, 1,254 Women of CBA in the Arabic Population (15-50 y) with regular menstrual cycles were randomly selected from five countries (Saudi Arabia, Egypt, Syria, Libya, and Sudan).
The mean (SD) age of the 1,254 studied females was 29.6 (8.5) years old. In total, 634 (50%) were married, 1,104 (88.0%) had a University education or above, 1,064 (84.4%) lived in urban areas, and 573 (45.7%) had normal body weight. Moreover, 524 (41.8%) were COVID-19 cases and 98 women (18.7%) reported menstrual changes (MCs). The 1,044 (83.5%) vaccinated females reported 418 (38.5%) MCs after being vaccinated, and these MCs resolved in 194 women (55.1%) after more than 9 months. Statistically significant relationships were observed between the reported MCs and the following variables: age, marital status, level of education, nationality, residence, and BMI. MCs were reported at 293(80.6) after the 2nd dose, and were mainly reported after 482 (46.1) Pfizer, 254 (24.3) Astrazenica, and 92 (8.8) Senopharm.
MCs among women of CBA after COVID-19 infection and vaccination are prevalent and complex problems, and had many determinates.
截至2021年9月2日，超过30000名接种新冠疫苗的女性向药品和保健品管理局（MHRA）的黄卡监测系统报告了月经变化。因此，美国国立卫生研究院（NIH）敦促研究人员调查新冠疫苗对月经的影响。因此，本研究旨在探讨新冠疫苗接种和/或感染新冠病毒后阿拉伯育龄妇女的月经变化及其与人口统计学、情绪和生活方式因素的相互关系。
2021年10月进行了一项横断面研究，使用经过阿拉伯语验证的自填问卷。从五个国家（沙特阿拉伯、埃及、叙利亚、利比亚和苏丹）的阿拉伯人群中随机选取了1254名月经周期规律的育龄妇女（15 - 50岁）。
1254名研究女性的平均（标准差）年龄为29.6（8.5）岁。其中，634名（50%）已婚，1104名（88.0%）拥有大学及以上学历，1064名（84.4%）居住在城市地区，573名（45.7%）体重正常。此外，524名（41.8%）曾感染新冠病毒，98名女性（18.7%）报告有月经变化（MCs）。1044名（83.5%）接种疫苗的女性在接种后报告了418次（38.5%）月经变化，其中194名女性（55.1%）的月经变化在9个月后得到缓解。报告的月经变化与以下变量之间存在统计学上的显著关系：年龄、婚姻状况、教育程度、国籍、居住地和体重指数。第二次接种后报告了293次（80.6%）月经变化，主要在接种辉瑞疫苗482次（46.1%）、阿斯利康疫苗254次（24.3%）和赛诺菲姆疫苗92次（8.8%）后报告。
新冠病毒感染和接种疫苗后，育龄妇女的月经变化是普遍且复杂的问题，并且有许多决定因素。
